Following extensive research, we have built a set of Personalised Support Services for cancer patients. These services are based on research and guidelines and offer evidence-based approaches to improve quality of life, while strengthening the relationship between the patient and their medical team.

They have been built by analysing thousands of scientific publications from high impact factor journals, as well as guidelines, medical literature, and databases. This allows CareAcross to match every patient’s needs with the most appropriate support.

We offer services among the following: 

• Breast cancer
• Lung cancer
• Bowel cancer
• Prostate cancer
• Other cancer types

CareAcross is a digital health company focusing on cancer. It provides 100% personalised support to people affected by cancer through reliable information, useful tools, psychological support & guidance from experts. Its vision is to facilitate faster, more effective oncology research, and interactions that will improve quality of life of patients and caregivers.

Eon uses the most advanced form of AI to create layered Computational Linguistics (CL) data science models. CL understands text and the linguistic structure of English, similar to how the human brain reads. EPM eliminates the noise by extracting clinically relevant information from radiology reports, saves FTE time, and improves patient outcomes.

EPM is the first and only solution to identify incidental pulmonary nodules on Magnetic Resonance (MR), X-Ray, and Computed Tomography (CT) reports. This update allows facilities to capture approximately 25% more incidental pulmonary nodules.

Eon is a digital health that has created the industry's first Intelligent Care platform. Our advanced AI integrates with your EHR to identify incidental findings with 98% accuracy. From there, our technology risk-stratifies patients, creates clear care plans, and automates patient/provider outreach to increase adherence and outcomes.

The company now works with more than 900 hospitals, and has impacted 2 million patients.